Shanghai Fosun Pharmaceutical (02196): FKC516 Injection for relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) has initiated a Phase II clinical trial in China.

Shanghai Fosun Pharmaceutical (02196) announced that recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the "Company")'s controlled subsidiary Fosun Kairui (Shanghai) Biotechnology Co., Ltd. has initiated a Phase II clinical trial in China for FKC516 Injection (hereinafter referred to as "FKC516") for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). FKC516 is a CD20-targeting autologous CAR-T cell therapy product licensed and introduced by the Group (i.e., the Company and its controlled subsidiaries/units, the same below). The Group enjoys, in accordance with the agreement (including mainly) exclusive rights to develop and commercialize the product globally across all disease areas. As of September 2026, the Group's cumulative R&D investment in FKC516 at the current stage was approximately RMB13.37 million (including licensing fees; unaudited). As of the date of this announcement (i.e., November 12, 2026), no CAR-T product targeting the same target has been approved for marketing in China.